Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 23 tags : Treatment save search
Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Published: 2021-06-23 (Crawled : 21:00) - biospace.com/
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: -1.09%
disease alzheimer treatment fda therapy antibody breakthrough therapy alzheimer’s alzheimer's disease alzheimer's designation lecanemab anti-amyloid beta
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
Published: 2021-06-23 (Crawled : 21:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -0.81%
H: 2.24%
C: 1.02%
treatment solid tumors ongoing phase 1 trial phase 2 keytruda
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults
Published: 2021-06-23 (Crawled : 18:00) - biospace.com/
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: 0.59%
H: 0.29%
C: -0.1%
treatment migraine injection
Dutch Biotech Acquires Corlieve to Develop Treatment for Temporal Lobe Epilepsy
Published: 2021-06-23 (Crawled : 17:00) - biospace.com/
RGNX | $16.08 -5.58% -5.91% 560K
|
Health Technology
|
| O: 0.52%
H: 1.49%
C: 0.5%
treatment biotech iot
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma
Published: 2021-06-23 (Crawled : 13:15) - globenewswire.com
YMAB | $14.97 -0.93% -0.94% 410K
|
Health Technology
|
| O: -1.41%
H: 3.88%
C: 2.06%
treatment
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
Published: 2021-06-23 (Crawled : 13:00) - globenewswire.com
XBIT | $7.9 -2.59% -2.66% 99K
|
Health Technology
|
| O: -0.12%
H: 1.73%
C: 1.17%
treatment cancer biotech iot trial pancreatic pancreas enroll
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
Published: 2021-06-23 (Crawled : 12:15) - globenewswire.com
COCP | $1.43 -1.39% 5.1K
|
Health Technology
|
| O: 0.0%
H: 2.67%
C: 2.29%
treatment phase 1 influenza trial cc-42344
New ReTo Project to Conduct Annual Iron Ore Tailings Treatment with Capacity of Three Million Tons and Anticipated Sales of Approximately RMB 280 Million
Published: 2021-06-23 (Crawled : 12:00) - prnewswire.com
RETO | $0.95 -3.06% -3.16% 110K
|
Non-Energy Minerals
|
| O: 20.51%
H: 20.57%
C: -6.38%
sales treatment
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
Published: 2021-06-23 (Crawled : 12:00) - globenewswire.com
LIFE | $1.625 2.2% 2.15% 260K
|
Health Technology
|
| O: -0.9%
H: 3.88%
C: 3.2%
treatment pharma
Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease
Published: 2021-06-23 (Crawled : 12:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.59%
H: 0.02%
C: -1.01%
disease treatment clinical trials trial rare
Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement
Published: 2021-06-23 (Crawled : 12:00) - biospace.com/
EDIT | $5.56 -0.89% -0.9% 1.7M
|
Health Technology
|
| O: 0.0%
H: 5.03%
C: 3.87%
treatment trial enroll
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Published: 2021-06-23 (Crawled : 12:00) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 1.32%
H: 4.07%
C: -2.12%
treatment positive nash liver
Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
Published: 2021-06-23 (Crawled : 02:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.34%
H: 0.02%
C: -2.29%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.48%
H: 0.29%
C: -0.43%
treatment therapy phase 3 cell carcinoma
Energy-based Non-invasive Medical Aesthetic Treatment System Market to reach $ 1.29 billion|Technavio
Published: 2021-06-23 (Crawled : 02:00) - prnewswire.com
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.1%
H: 0.74%
C: -0.58%
treatment energy aesthetic
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.